3//SEC Filing
Atlas Venture Associates IX, L.P. 3
Accession 0000899243-18-008775
CIK 0001622229other
Filed
Mar 27, 8:00 PM ET
Accepted
Mar 28, 9:10 PM ET
Size
9.7 KB
Accession
0000899243-18-008775
Insider Transaction Report
Form 3
Atlas Venture Fund IX, L.P.
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (83,067 underlying)Series A Preferred Stock
→ Common Stock (3,184,446 underlying)
Atlas Venture Associates IX, LLC
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (83,067 underlying)Series A Preferred Stock
→ Common Stock (3,184,446 underlying)
Atlas Venture Associates IX, L.P.
10% Owner
Holdings
Series A Preferred Stock
→ Common Stock (3,184,446 underlying)Series B Preferred Stock
→ Common Stock (83,067 underlying)
Footnotes (2)
- [F1]Each share is convertible on a 1.5701314513884-for-1 basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The shares have no expiration date.
- [F2]The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any.
Documents
Issuer
Unum Therapeutics, Inc.
CIK 0001622229
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001671208
Filing Metadata
- Form type
- 3
- Filed
- Mar 27, 8:00 PM ET
- Accepted
- Mar 28, 9:10 PM ET
- Size
- 9.7 KB